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Abstract
Background:A commercially available nanocrystalline hydroxyapatite paste Ostim® has been
reported in few recent studies to surpass other synthetic bone substitutes with respect to the
observed clinical results. However, the integration of this implantable material has been
histologically evaluated only in animal experimental models up to now. This study aimed to evaluate
the tissue incorporation of Ostim® in human cancellous bone after reconstructive bone surgery for
trauma.
Methods:Biopsy specimens from 6 adult patients with a total of 7 tibial, calcaneal or distal radial
fractures were obtained at the time of osteosynthesis removal. The median interval from initial
operation to tissue sampling was 13 (range 3–15) months. Samples were stained with Masson-
Goldner, von Kossa, and toluidine blue. Osteoid volume, trabecular width and bone volume, and
cortical porosity were analyzed. Samples were immunolabeled with antibodies against CD68,
CD56 and human prolyl 4-hydroxylase to detect macrophages, osteoblasts, and fibroblasts,
respectively. TRAP stainings were used to identify osteoclasts.
Results:Histomorphometric data indicated good regeneration with normal bone turnover: mean
osteoid volume was 1.93% of the trabecular bone mass, trabecular bone volume – 28.4%,
trabecular width – 225.12 μm, and porosity index – 2.6%. Cortical and spongious bone tissue were
well structured. Neither inflammatory reaction, nor osteofibrosis or osteonecrosis were observed.
The implanted material was widely absorbed.
Conclusion:The studied nanocrystalline hydroxyapatite paste showed good tissue incorporation.
It is highly biocompatible and appears to be a suitable bone substitute for juxtaarticular
comminuted fractures in combination with a stable screw-plate osteosynthesis.
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Background
Operative reconstruction of bone defects beyond a certain
size is mandatory and still remains a challenge to trauma
and orthopedic surgeons. Every year, millions of people
are suffering from bone defects arising from trauma,
tumor or bone diseases [1]. In about 10% of all recon-
structive operations because of traumatic, resectional, or
congenital defects, bone transplants and bone substitute
materials are necessary [2].
Autologous cancellous bone remains the "gold standard"
in the reconstruction of bone defects because of its unsur-
passed biological activity even in implant sites with low
osteogenic potential. The main disadvantages of human
autografts are their limited quantity and the morbidity
associated with their harvest [3,4]. Human allografts offer
an abundantly available alternative, which circumvents
the potential morbidity of autograft harvest, but relies on
a sophisticated bone banking system and carries the
potential of disease transmission and immunogenicity.
Furthermore, the structural, mechanical, and resorption
properties of allografts are usually much altered by
processing, preservation, and sterilization techniques [5].
The relative concerns over the use of either autograft or
allograft have led to the development of numerous
entirely synthetic bone graft substitutes.
Mineral bone substitutes have been in widespread clinical
use for a number of years. The most commonly used min-
eral substitutes for bone defect and trauma applications as
implant coatings and defect fillers are thermally processed
hydroxyapatite (HA) and tricalcium phosphate. Due to
their osteoconductive potential and the absence of anti-
genicity, osteointegration usually occurs quickly and reli-
ably in sterile and well vascularized sites [6].
Hydroxyapatite has a similar crystal structure to that of
bone mineral and has been investigated as a bone replace-
ment material for over 30 years [7,8].
The HA used in the present study is a fully synthetic and
fully resorbable injectable nanocrystalline paste
[Ca10(PO4)6(OH)2] (Ostim®, Osartis, Obernburg, Ger-
many), and consists of a suspension of pure HA in water
prepared by a wet chemical reaction. The needle shaped
HA crystals form agglomerates in transmission electron
microscopy (Fig. 1). The average crystallite size is 100 nm/
20 nm/3 nm, the atomic ratio of calcium-phosphorus is
1.67. Ostim® paste does not harden after application into
the bone and is free of endothermical heating. It is charac-
terized by a large bioactive specific surface area of 106 m2/
g [9]. The Ostim® syringe in the double sterile pack can be
used to apply paste to the bone defect directly or by means
of applicators. Although Ostim® has already been success-
fully used in parodontal surgery [10,11] and is approved
for clinical use as bone substitute, no histological observa-
tions in humans have been reported so far.
The current study presents the first histological observa-
tions on the incorporation of this nanocrystalline HA
paste in human cancellous bone in a group of patients,
treated for various types of bone fractures.
Methods
Ostim® was used to fill bone defects in human patients,
prospectively recruited for the treatment of traumatic
bone defects of radius, calcaneus and tibia. Between June
2004 and October 2005 seven biopsies were performed in
six patients at the time of removal of their fracture fixation
devices (Table 1). The study was conducted in accordance
with the Declaration of Helsinki (1996 revision). The eth-
ics committee of the University of Heidelberg approved
the study. Specific informed consent for participation in
the research was obtained from all patients.
Reconstruction of distal radial defects
Two patients had a total of three fractures of the distal
radius. In the female patient with bilateral radius frac-
tures, biopsies were taken from both sides during synchro-
nous plate removal. A standard palmar approach
followed by a carpal canal dissection was used in all cases.
The correct radius length was achieved by reduction with
the use of a sterile hand extension set. The correct reduc-
Table 1: Characteristics of patients from whom bone biopsies were obtained.
No Sex Age (years)* Location of fracture Interval to biopsy (mo)
1 F 31 Tibial head 14
2 M 31 Tibial head 13
3 M 54 Calcaneus 15
4 M 44 Calcaneus 3
5 M 44 Distal radius 13




44 (median) 13 (median)
* age at the time of biopsyBMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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tion and metal plate position were radiologically con-
firmed. Cases at a high risk of perioperative redislocation,
were additionally treated with the use of temporary 1.6
mm Kirschner-wires. All K-wires and none angularly sta-
ble screws used as repositioning aids were removed and
replaced with LCP-screws before the end of the operation.
The final step of the operation following the definitive fix-
ation of the plate (angular stable 3.5 mm titanium screw-
plate system made by Synthes/Oberndorf-Switzerland),
was the void filling with Ostim®. The median quantity
used was 2 ml. The paste was inserted from the palmar
side into the metaphyseal defect area (Fig. 2).
Reconstruction of calcaneal defects
An extended lateral approach with an L-shaped incision
was performed, beginning proximally, over the lateral
aspect of the heel. It was then continued distally between
the lateral malleolus and the posterior and inferior border
of the heel. The peroneal tendons were then mobilized
within their sheath and held back. After exposing the lat-
eral calcaneal surface, which allowed the identification of
the fracture lines, anatomic reduction was performed. In
most cases we began with the reduction of the tuberosity
fragment with the aid of a Schanz screw inserted dorsally.
Further anatomical reduction was also conducted using
various reduction aids, e.g. provisional K-wires. Special
attention was paid to the exact reconstruction of the pos-
terior facet. After realigning the impacted area, defect
zones of various volumes normally remained behind. At
that time-point the need of HA defect filling was defini-
tively determined. The defect was then filled with a
median volume of 5 ml Ostim® after partial fixation of the
bone using a calcaneal plate (Calcaneus Conventional®
100% titanium plate – Litos Company, Hamburg, Ger-
many). The osteoreconstructive result was examined
intraoperatively by diaphanoscopy.
Reconstruction of tibial head defects
A decision about the type of surgical access to be used (lat-
eral, medial, posterolateral or biportal) was based upon
the fracture morphology. The deep incision went straight
down to the bone leaving a narrow border of fascia
Pure nanocrystalline hydroxyapatite (Ostim®) forms aggregates of needle-shaped crystals in transmission electron microscopy  (magnification: left 7500x; right 150 000x) Figure 1
Pure nanocrystalline hydroxyapatite (Ostim®) forms aggregates of needle-shaped crystals in transmission electron microscopy 
(magnification: left 7500×; right 150 000×)BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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attached to the tibia. The impacted articular surface had to
be elevated. In order to secure the achieved reposition K-
wires were temporary inserted. The cavity walls were
coated with the absorbable hydroxyapatite paste (Ostim®)
before a hydroxyapatite ceramic core (Cerabone®) was
inserted. Once the ceramic was inserted, it was then cov-
ered with more hydroxyapatite paste before closing the
cortical window. The bone voids were filled with 5 ml to
10 ml Ostim® (median volume – 9 ml). Repositioning
results were preserved by the implantation of an angular
stable titanium screw-plate system (Synthes/Oberndorf-
Switzerland).
Histological preparations
Cylindrical biopsy specimens measuring 1.0–3.0 cm in
length with a diameter of 5 mm, corresponding to a vol-
ume of 0.2–0.6 ml, were obtained for histological and
immunohistochemical analysis with a water-cooled hol-
low drill (DBCS Diamond Bone Cutting System, Biomet
Merck, Darmstadt, Germany) (Fig. 3a and Fig. 3b). After
removal of the metal plates, the drill was positioned
towards the center of the substitute material implantation
site by using former screw holes, diaphanoscopy, and X-
ray images for orientation. In cases of tibial head fractures
biopsies were taken only from the places where Ostim®
had been applied. The tissue probes were fixed in 4% For-
maldehyde in PBS-buffer. Using the method of Donath
and Breuner 1982 [12] undecalcified bone samples were
embedded in Technovit 9100®  New (Heraeus Kulzer,
Hanau, Germany) – a low temperature methylmethacr-
ylate embedding system that significantly improves tissue
antigenicity preservation allowing polymerisation at -
20°C and quantitative assessment of bone-matrix pro-
teins. Thin 7 μm sections were stained with Masson-Gold-
ner, von Kossa, and toluidine blue. Osteoid volume (%),
trabecular width, trabecular bone volume (%), and corti-
An angularly stable screw-plate system is used for fixation Figure 2
An angularly stable screw-plate system is used for fixation. The metaphyseal defect of the radius is filled with a nanocrystalline 
hydroxyapatite paste through a free screw-hole in the metal plate.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
Page 5 of 14
(page number not for citation purposes)
The DBCS drill (Biomet Merck, Darmstadt, Germany) is used to obtain a cylindrical biopsy Figure 3a
The DBCS drill (Biomet Merck, Darmstadt, Germany) is used to obtain a cylindrical biopsy. The plate is still in place at that 
time. B Intraoperative view of the radius after drilling and plate removal. The biopsy hole has the diameter of a screw hole, so 
stability of the reconstructed bone is threatened in no way.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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cal porosity (%) were analyzed. Histological examination
and photography were performed using a Zeiss Axiophot
microscope (Zeiss, Oberkochen, Germany). All bone sam-
ples were additionally labelled with antibodies against
CD 68, CD56 and human prolyl 4-hydroxylase (h4Ph).
The CD68 marker, which stains lysosomes and is there-
fore mainly found in phagocyting cells, was used to iden-
tify macrophages. The CD56 was used for recognizing
osteoblasts. Prolyl 4-hydroxylase plays a central role in the
synthesis of all collagen types and is a marker for collagen
producing cells [13]. Therefore it was used for detection of
fibroblasts. The following mouse anti-human antibodies
were used: CD68, 1:500 (clone KP1; Dako, Germany);
h4Ph, 1:400 (Medicorp, Montreal, Canada); CD56, 1:400
(Santa Cruze, Germany). For screening of h4Ph, CD 68
and CD56 expression the primary antibodies were diluted
in 0.1 M Na-phosphate buffer, pH 7.0, containing 0,5%
protease-free bovine serum albumin. Immunostainings
were performed using the conventional alkaline phos-
phatase anti-alkaline phosphatase (APAAP) technique.
Immunohistochemical TRAP (tartrate-resistant acid phos-
phatase) -staining (mouse-antihuman antibody, 1:100;
Dako, Germany) was used to identify osteoclasts via ABC
detection method. The sections were finally counter-
stained with hematoxylin and mounted. Histomorphom-
etry was performed using point counting and linear
intercept techniques.
Results
The postoperative course after fracture stabilization and
the above described defect reconstruction was uneventful.
All soft tissue wounds showed primary healing; fracture
consolidation was not retarded (Fig. 4a, b, c, d). Clinical
and radiological follow-up did not indicate inflammatory
tissue reactions or osteolysis. Implant removal was timed
according to the standards at our institution, provided
that fracture consolidation had been confirmed radiolog-
ically. One patient with calcaneal fracture required early
implant removal after three months because of clinically
suspected local infection. However, infection could not be
confirmed microbiologically and the fracture was already
consolidated. The postoperative course after implant
removal and biopsy was also uneventful in all patients.
Histological analysis of bone biopsy showed well struc-
tured cortical and cancellous bone tissue with focal fibro-
sis of the medullary space. All biopsy specimens
contained residues of the substitute material. Within the
medullary space remaining particles of amorphic HA
implant material were seen in all samples (Fig. 5). In these
areas low number of macrophages and fibroblasts were
detected (Fig. 6, 7); the implant particles were easily seen
and covered by newly formed bone. Bone healing, and
ramifications of trabecular bone could be seen between
the implant particles. In all specimens, new bone forma-
tion was clearly visible beginning with the deposition of
osteoid directly onto the substitute material and second-
ary mineralization in the presence of cell layers resem-
bling osteoblasts (Fig. 8). Osteoblasts were regularly
distributed on the surface of bone trabecles (Fig. 9). The
mean trabecular bone volume constituted 28,4 ± 3,82%
with a mean trabecular width of 225,12 ± 16,30 μm. The
osteoid volume comprised approximately 1.93 ± 0,22%
of the trabecular bone mass. The osteoclastic resorptive
surface was less than 0,1% of the surface of the trabecular
bone. Singular osteoclasts were found within the bone
trabecles (Fig. 10). The porosity index was 2,60 ± 1.33%
of the bone tissue. Generally, there was an intimate con-
tact between implant and bone, without any fibrous inter-
face. Residues of the hydroxyapatite were connected by
new trabecles, which showed a tendency to form spatial
patterns reminiscent of the mechanical orientation seen
in normal cancellous bone. Cells in close contact with the
implant material either resembled osteoblasts or, in some
sites, appeared to be resorbing the material. These latter
cells contained several nuclei and were lying in shallow
lacunae on the hydroxiapatite surface possibly resulting
from their resorptive activity. Adjoining soft tissues did
not exhibit any signs of inflammatory tissue reaction.
Instead, medullary tissue consisted of differentiated fat
cells and blood vessels. Cavities within the foreign mate-
rial also contained adipocytes and blood vessels. While in
some areas larger polynuclear cells were visible adjacent
to the inner wall, in other locations a circular deposition
of new bone had already occurred within these cavities.
In summary, the morphological features of the bone tis-
sue showed good regeneration of the bone with normal
bone turnover. There was neither inflammatory reaction,
nor osteonecrosis. The implanted material was widely
resorbed.
Discussion
Limited availability and donor site morbidity represent
major disadvantages of autografts. As many as 39% of
patients may complain of chronic pain at the donor site
after iliac crest harvest [3]. Furthermore, there is an added
operative time and blood loss inherent in obtaining it.
Other complications include arterial and nerve injury,
infection, cosmetic deformity, gait disturbance, fracture,
hernia, and sacroiliac joint injury [4]. Allografts are
known to be immunogenic and virus transmission
remains a major cause of concern. For some of these prob-
lems, synthetic HA bone substitutes have been considered
a reasonable alternative. They are known to be biocom-
patible, osteoconductive, non-toxic, non-inflammatory,
and non-immunogenic agents [14,15]. Due to their com-
paratively low mechanical stability, however, they should
be used primarily for the reconstruction of metaphyseal
bone deficiencies and less for major diaphyseal defects.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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X-ray images of the hand of patient No. 5 three months after the reconstruction (4a and 4b) and after the plate removal 10  months later (4c and 4d) Figure 4
X-ray images of the hand of patient No. 5 three months after the reconstruction (4a and 4b) and after the plate removal 10 
months later (4c and 4d). New bone has refilled the metaphyseal defect.
4a 4b
4c 4dBMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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Typical clinical indications, therefore, would be juxtaartic-
ular fractures, for example, in the distal radius, proximal
humerus, proximal and distal tibia, or calcaneus. They
also represent an interesting alternative for reconstructing
defects in the same locations resulting from the resection
of benign bone tumors. The major problem with sintered
HA bone substitutes (ceramics) seems to be their failure to
undergo sufficient physiological remodelling. This short-
coming is attributable mainly to the heating of mineral
beyond 1000°C during the sintering process. This results
in the transformation of the tiny (<60 nm) primary HA
crystallites into significantly larger crystals, which are dif-
ficult to break down for osteoclasts. This leads to a rela-
tively poor bioresorbability and limiting handling
characteristics [16]. While the handling characteristics
were improved by the introduction of malleable HA
cements, bioresorbability has remained a problem. A
great variety of calcium phosphate-based injectable bone
substitutes are now commercially available: Bone Source®
(Howmedica, USA), Norian SRS® (Norian, USA), Cemen-
tek®  (Teknimed SA, France), Mimics®  (Biomet, USA),
Biocement D® (Biomet Merck Ltd, Germany), Biobon®
(Biomet Merck Ltd, Germany; in USA distributed as α-
BSM™, ETEX, USA), True bone® (ETEX, USA) etc. Up to
now there has been accumulating evidence that osteo-
clasts are able to resorb these substances, though not with
the same speed for the different representatives [17,18]. It
will be interesting to directly compare in future studies the
resorption of Ostim® and the mentioned bone substitutes,
and to investigate probable advantages of the combined
use of Ostim® with biphasic TCP/HA granules or other
newly developed materials [19].
Remnants of nanocrystalline hydroxyapatite paste in the medullary space (white arrow) Figure 5
Remnants of nanocrystalline hydroxyapatite paste in the medullary space (white arrow). The border between nanocrystalline 
hydroxyapatite paste and newly formed cancellous bone is shown (black arrows). Histological section, Masson-Goldner stain-
ing, 40×.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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To overcome the mentioned disadvantage of ceramics and
cements, a new technology was used for the production of
Ostim®. It is synthesized by a wet chemical reaction of pre-
cipitation under permanent pH control using CaO dis-
persed in water under constant stirring to maintain a
suspension state and H3PO4  as starting material. The
amounts of both starting materials and water lead to sus-
pension containing 5.5% of nanosized HA crystals. This
suspension with a pH of 7.5 is concentrated using filtra-
tion and subsequent evaporation process leading to a
high viscous paste with an HA content of 35% and a spe-
cific surface area of 106 m2/g [9]. It does not harden off
when mixed with blood or spongiosa and its volume sta-
bility enables it to resist bleeding pressure. Simultane-
ously, its viscosity enables it to be applied to form-fit in
close contact with the bone [20].
The above mentioned putative functional advantages of
Ostim® were proved in humans by two large clinical stud-
ies in the sphere of human dentofacial surgery. In the first
study, Zuev et al. in 1996 found Ostim® to be not inferior
to bone transplant and devoid of its shortcomings in the
treatment of 395 patients with periodontal defects,
including mainly periodontal abscesses. Control physical
examinations were performed 3, 7, and 21 days and 1, 3,
and 6 months after the operation. Control X-rays were
performed 6 months after surgery. Complications in the
group of 200 patients treated with Ostim® were only 1.5%
and never involved the site of osteoplasty, whereas the
complication rate was 3.6% in the group of 195 patients
treated with chemically processed bone xenotransplants
[10]. In the second study, Bezrukov et al. reported excel-
lent clinical results with the use of Ostim® in 49 patients
Low number of macrophages (arrows) localized in close vicinity to particles of the hydroxyapatite paste Figure 6
Low number of macrophages (arrows) localized in close vicinity to particles of the hydroxyapatite paste. Histological section, 
CD68 immunostaining.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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who underwent cystectomy for benign cyst-tumors of the
jaws. One month after the operation defects were already
beginning to lose their borders, three months after the
reconstruction a full bone regeneration was radiologically
observed at the place of paste application, and 6 months
after the manipulation mature bone tissue with a normal
configuration and optical density was confirmed at X-ray
films in all cases. No procedure-related complications
were reported [11].
Apart from the above two trials, no other reports on the
applicability of Ostim® in human medicine are currently
to be found in world literature. Experiments with the
paste were performed in several animal studies, some of
them including histological observations. It was well tol-
erated in dogs, sheep, rabbits and pigs. The first one of
these studies, which investigated the histological integra-
tion of Ostim®  in the dental wall of four dogs, was
reported by Grigor'ian et al. in 2000, who revealed excel-
lent osteoinductive and osteoconductive properties of
Ostim® [21]. Thorwarth et al. reported 44.2–53.9% miner-
Low number of fibroblasts (arrows) distributed diffusely in the medullary space containing nanocrystalline hydroxyapatite paste Figure 7
Low number of fibroblasts (arrows) distributed diffusely in the medullary space containing nanocrystalline hydroxyapatite 
paste. Histological section, h4Ph immunostaining, 24×.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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alized bone substance in pigs after 3–6 months in the
region of the reconstructed defect and 0% remnants of the
bone substitute 6 months after its application [22]. As the
paste does not harden in situ, cell migration into the
implantation area coincided with revascularization. Frag-
mentation of the paste was observed in all animal models
immediately after implantation. That fragmentation into
round particles of different size must be regarded as an
essential step toward successful reconstitution of tissue
integrity. It enables cellular infiltration of the implanta-
tion site and enables osteoblasts to perform bone forma-
tion in an osteoconductive manner. After implantation of
the nanocrystalline HA paste into tibial head defects of
sheep, the voids were completely filled with new bone
even after 60 days. Due to proceeding bone healing, ram-
ifications of trabecular bone could be seen between the
implant particles. This spatial ingrowth pattern, taken
together with the stimulation of osteoblast activity, sup-
ports complete reconstitution (e.g. bridging) of critical-
size defects of animals within 4 weeks [2].
Although our study reports on a series of biopsy speci-
mens taken at different time intervals from human
patients with various types of fractures rather than from
laboratory animals with standardized defects, the basic
pattern of integration of the nanocrystalline hydroxyapa-
tite appears to be the same in animals and humans: there
is no fibrous interface, but instead an intimate contact
between new bone and substitute material is established.
At an early stage, a disintegration of the substitute mate-
rial occurs and new bone starts to form trabeculae and
osteonal structures like in conventional fracture healing.
Well structured trabecular bone tissue (white arrow) with osteoid on the trabecular surface (black arrows) Figure 8
Well structured trabecular bone tissue (white arrow) with osteoid on the trabecular surface (black arrows). Histological sec-
tion, von Kossa staining, 8×.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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Our findings, arising from the treatment of comminuted
juxtaarticular fractures confirmed the good clinical results
from the application of the nanocrystalline HA paste in
dentofacial surgery. Moreover, the first histological obser-
vations on the integration of Ostim® made in our small
group of patients perfectly agree with the previous histo-
logical findings in experimental animal models.
Conclusion
The nanocrystalline HA paste is easy to prepare and easy
to apply by syringe in the operating room. A second surgi-
cal procedure to harvest autologous bone is not necessary,
and complications at the donor site are therefore avoided.
There is no risk of transmitting any disease. This safe and
osteoconductive HA paste appears suitable for filling
bone defects and bone cavities, showing resorption and a
rapid osseous integration. Clinical results were compara-
ble to those obtained in patients treated with autograft
implants, and histology revealed that fracture healing
went undisturbed and active resorption was performed by
osteoclasts. This material appears to be mechanically and
biologically efficient and safe. It is able to preserve well its
volume, but not its form, so for the purposes of fracture
reconstructions it should be always used in combination
with a stable screw-plate osteosynthesis.
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A layer of red-stained osteoblasts (white arrows) are found on the surface of newly formed trabecular bone Figure 9
A layer of red-stained osteoblasts (white arrows) are found on the surface of newly formed trabecular bone. Histological sec-
tion, CD56 immunostaining, 40×.BMC Musculoskeletal Disorders 2006, 7:50 http://www.biomedcentral.com/1471-2474/7/50
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